NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.
Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.
Epigenomics also said it will use its proprietary OncoSign identification approach through a collaboration with its partner CellTrend for rapid identification of biomarkers in a panel of human tumor cell lines.
Financial terms of the agreement were not released.